aibioIMDX Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics (IMDX) news
Insight Molecular Diagnostics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IMDX, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Insight Molecular Diagnostics news
We have not published a story on Insight Molecular Diagnostics yet. When there is news, it will appear here.
Insight Molecular Diagnostics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $4.1 million | $1.9 million |
| Research and development | $15.9 million | $9.8 million |
| Net income (loss) | -$50.2 million | -$60.7 million |
| Cash from operations | -$22.2 million | -$20.7 million |
| Cash and equivalents | $11.6 million | $8.6 million |
Questions about Insight Molecular Diagnostics
What is the ticker symbol of Insight Molecular Diagnostics?
Insight Molecular Diagnostics Inc. trades under the ticker IMDX on NASDAQ.
Where is Insight Molecular Diagnostics listed?
Insight Molecular Diagnostics Inc. is listed on NASDAQ.
Which country or territory is Insight Molecular Diagnostics listed under?
Our directory records Insight Molecular Diagnostics Inc. under United States.
Does aibio.space cover Insight Molecular Diagnostics?
aibio.space lists Insight Molecular Diagnostics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What was Insight Molecular Diagnostics's revenue last year?
$4.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Insight Molecular Diagnostics profitable?
Insight Molecular Diagnostics Inc. reported a net loss of $50.2 million for the fiscal year ended Dec 31, 2025, and used $22.2 million of cash in operations, per its annual report to the SEC.
How much does Insight Molecular Diagnostics spend on research and development?
$15.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Insight Molecular Diagnostics have?
$17.8 million in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: Insight Molecular Diagnostics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). Source
Stock chart
Listing details
- Company
- Insight Molecular Diagnostics Inc.
- Ticker
- IMDX
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction